Treatment of hyperprolactinemia: a systematic review and meta-analysis

Hyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to provide evidence-based recommendations for practitioners....

Full description

Saved in:

Bibliographic Details
Published in:	Systematic reviews Vol. 1; no. 1; p. 33
Main Authors:	Wang, Amy T, Mullan, Rebecca J, Lane, Melanie A, Hazem, Ahmad, Prasad, Chaithra, Gathaiya, Nicola W, Fernández-Balsells, M Mercè, Bagatto, Amy, Coto-Yglesias, Fernando, Carey, Jantey, Elraiyah, Tarig A, Erwin, Patricia J, Gandhi, Gunjan Y, Montori, Victor M, Murad, Mohammad Hassan
Format:	Journal Article
Language:	English
Published:	England BioMed Central 24-07-2012 BMC
Subjects:	Evidence-Based Medicine Humans Hyperprolactinemia Hyperprolactinemia - therapy Macroprolactinoma Microprolactinoma Treatment
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Hyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to provide evidence-based recommendations for practitioners. Through this review, we aimed to compare efficacy and adverse effects of medications, surgery and radiotherapy in the treatment of hyperprolactinemia. We searched electronic databases, reviewed bibliographies of included articles, and contacted experts in the field. Eligible studies provided longitudinal follow-up of patients with hyperprolactinemia and evaluated outcomes of interest. We collected descriptive, quality and outcome data (tumor growth, visual field defects, infertility, sexual dysfunction, amenorrhea/oligomenorrhea and prolactin levels). After review, 8 randomized and 178 nonrandomized studies (over 3,000 patients) met inclusion criteria. Compared to no treatment, dopamine agonists significantly reduced prolactin level (weighted mean difference, -45; 95% confidence interval, -77 to -11) and the likelihood of persistent hyperprolactinemia (relative risk, 0.90; 95% confidence interval, 0.81 to 0.99). Cabergoline was more effective than bromocriptine in reducing persistent hyperprolactinemia, amenorrhea/oligomenorrhea, and galactorrhea. A large body of noncomparative literature showed dopamine agonists improved other patient-important outcomes. Low-to-moderate quality evidence supports improved outcomes with surgery and radiotherapy compared to no treatment in patients who were resistant to or intolerant of dopamine agonists. Our results provide evidence to support the use of dopamine agonists in reducing prolactin levels and persistent hyperprolactinemia, with cabergoline proving more efficacious than bromocriptine. Radiotherapy and surgery are useful in patients with resistance or intolerance to dopamine agonists.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-4 content type line 23 ObjectType-Undefined-3
ISSN:	2046-4053 2046-4053
DOI:	10.1186/2046-4053-1-33